Top Markets
#1 Helium Helium +45.70%
#2 TENDIES TENDIES +42.44%
#3 Pons Pons +36.20%
#4 UnifAI Network UnifAI Network +19.28%
#5 Seeker Seeker +18.90%
#6 Songbird Songbird +12.44%
#7 OSK OSK +10.10%
#8 Bounce Bounce +9.81%
#9 DAPPOS DAPPOS +9.74%
#10 Lista DAO Lista DAO +8.75%
Coin of the day
Helium Helium
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
शेयरों में रैंक #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
शेयर मूल्य
$9.50
अंतिम समन्वयन: 2025-01-08
मार्केट कैप
$819.52M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Poseida Therapeutics, Inc. (PSTX)

श्रेणी

Healthcare
Poseida Therapeutics, Inc. (PSTX) के लिए राजस्व
Sep 2024 में राजस्व TTM: $150.86M
Poseida Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान राजस्व (TTM) $150.86M है। 2022 में, कंपनी ने $130.36M का राजस्व अर्जित किया जो 2021 के $31.24K के राजस्व से की वृद्धि है। राजस्व वह कुल आय है जो कंपनी अपने उत्पादों या सेवाओं की बिक्री से उत्पन्न करती है। लाभ की तुलना में इसमें कोई खर्च घटाया नहीं जाता।
Poseida Therapeutics, Inc. के लिए 2016 से 2026 तक की राजस्व इतिहास
प्रत्येक वर्ष के अंत में राजस्व
वर्ष राजस्व परिवर्तन
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए राजस्व
कंपनी राजस्व राजस्व में अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH